Caxton Associates LP Bluebird Bio, Inc. Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $300,381 - $402,829	99,464 Added 187.93%	152,389 $463,000
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $147,660 - $266,212	52,925 New	52,925 $174,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $571,905 - $1.13 Million	-152,508 Reduced 69.27%	67,646 $428,000
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $549,127 - $976,848	186,778 Added 559.62%	220,154 $911,000
Q1 2022 May 16, 2022	SELL	$4.07 - $10.6 $237,867 - $619,506	-58,444 Reduced 63.65%	33,376 $162,000
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $822,707 - $1.5 Million	91,820 New	91,820 $917,000

27M

191K

299K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $561M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.